Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Baxter Pays $24 Million To Bring JV In-house

publication date: Jan 30, 2008

Baxter International will take its Shanghai Baxter JV completely in-house by buying the 40% stake in the JV that had been owned by Worldbest Treeful Pharmaceutical. Worldbest is in financial trouble, and the Bank of China ordered the JV stake to be put up for auction. Worldbest Treeful originally invested $4.8 million for a 40% participation in the venture. Baxter paid 180 million RMB, about $24.3 million, to acquire the position. More details...

Stock Symbol: (NYSE: BAX) 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here